# Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers

> **NCT01275612** · PHASE1 · WITHDRAWN · sponsor: **Mario Negri Institute for Pharmacological Research**

## Conditions studied

- Solid Tumors
- Acute Kidney Injury

## Interventions

- **BIOLOGICAL:** Mesenchymal stromal cell infusion

## Key facts

- **NCT ID:** NCT01275612
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-11
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-03-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Patients evaluated so far could not be enrolled because they did not meet the primary criterion of acute renal failure provided by the study protocol
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275612, "Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01275612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*